Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6571855 | 1.00 | CYP4F2 (0.42) | CYP4F2CYP4A11USP2ALDH1A1LMNA | |
| SCHEMBL9505588 | 0.97 | CYP4F2 (0.46) | CYP4F2CYP4A11USP2ALDH1A1LMNA | |
| SCHEMBL5187599 | 0.97 | CYP4F2 (0.46) | CYP4F2CYP4A11USP2ALDH1A1LMNA | |
| SCHEMBL9504407 | 0.97 | CYP4F2 (0.44) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL8817671 | 0.95 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1LMNATSHR | |
| SCHEMBL9508114 | 0.95 | CYP4F2 (0.47) | CYP4F2CYP4A11ALDH1A1LMNATSHR | |
| SCHEMBL8114191 | 0.92 | CYP4F2 (0.35) | CYP4F2CYP4A11USP2ALDH1A1LMNA | |
| SCHEMBL9505551 | 0.89 | CYP4F2 (0.36) | CYP4F2CYP4A11USP2ALDH1A1LMNA | |
| SCHEMBL15426944 | 0.86 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL19618749 | 0.84 | CYP4F2 (0.44) | CYP4F2CYP4A11ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025069725-A1 | POLISHING COMPOSITION, CONCENTRATED SOLUTION OF POLISHING COMPOSITION, AND POLISHING METHOD | 株式会社フジミインコーポレーテッド | 2025-04-03 | — | — | WO | disclosed |
| US-20240301114-A1 | POLYCARBONATE DIOL AND PRODUCING METHOD THEREOF, AND POLYURETHANE AND ACTIVE ENERGY RAY-CURABLE POLYMER COMPOSITION BOTH FORMED USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-12 | — | — | US | disclosed |
| CN-117794373-A | Antibacterial/antiviral agent composition, antibacterial/antiviral structure, and method for producing antibacterial/antiviral structure | 日华化学株式会社 | 2024-03-29 | — | — | CN | disclosed |
| US-11878067-B2 | Gel compositions containing copolymer of vinylpyrrolidone and acrylic acid | L'OREAL (FR) | 2024-01-23 | — | — | US | disclosed |
| WO-2023013687-A1 | ANTIBACTERIAL/ANTIVIRAL AGENT COMPOSITION, ANTIBACTERIAL/ANTIVIRAL STRUCTURE, AND ANTIBACTERIAL/ANTIVIRAL STRUCTURE PRODUCTION METHOD | 日華化学株式会社 | 2023-02-09 | — | — | WO | disclosed |
| EP-3459987-B1 | POLYCARBONATE DIOL AND PRODUCING METHOD THEREOF, AND POLYURETHANE AND ACTIVE ENERGY RAY-CURABLE POLYMER COMPOSITION BOTH FORMED USING SAME | MITSUBISHI CHEM CORP (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20210030635-A1 | GEL COMPOSITIONS CONTAINING COPOLYMER OF VINYLPYRROLIDONE AND ACRYLIC ACID | L'ORÉAL (FR) | 2021-02-04 | — | — | US | disclosed |
| WO-2021021978-A1 | COMPOSITIONS CONTAINING COPOLYMER OF VINYLPYRROLIDONE AND ACRYLIC ACID AND FILM FORMING AGENT | L'OREAL (FR) | 2021-02-04 | — | — | WO | disclosed |
| EP-3720562-A1 | NAIL COMPOSITIONS CONTAINING LATEX AND SULFOPOLYESTER COMPOUND | L'OREAL (FR) | 2020-10-14 | — | — | EP | disclosed |
| EP-3083881-B1 | MOLECULAR GLASS MIXTURES FOR ORGANIC ELECTRONICS APPLICATIONS | MOLECULAR GLASSES INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-0393149-B1 | VINYL ETHER TERMINATED ESTER AND URETHANE RESINS FROM BIS(HYDROXYALKYL)CYCLOALKANES | AlliedSignal Inc. (US) | 1992-12-09 | — | — | EP | disclosed |
| EP-0402408-A4 | SOLVENT RESISTANT IRRADIATION CURABLE COATINGS | — | 1992-05-13 | — | — | EP | disclosed |
| EP-0402408-A1 | SOLVENT RESISTANT IRRADIATION CURABLE COATINGS | GAF CHEMICALS CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
| EP-0393149-A1 | VINYL ETHER TERMINATED ESTER AND URETHANE RESINS FROM BIS(HYDROXYALKYL)CYCLOALKANES. | ALLIED SIGNAL INC (US) | 1990-10-24 | — | — | EP | disclosed |
| US-4885319-A | DIVINYL ETHERS USED AS REACTIVE DILUENT FOR EPOXY RESINS | GAF CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| WO-1989007986-A1 | SOLVENT RESISTANT IRRADIATION CURABLE COATINGS | GAF CHEMICALS CORPORATION (US) | 1989-09-08 | — | — | WO | disclosed |
| WO-1989006228-A1 | VINYL ETHER TERMINATED ESTER AND URETHANE RESINS FROM BIS(HYDROXYALKYL)CYCLOALKANES | ALLIED-SIGNAL INC. (US) | 1989-07-13 | — | — | WO | disclosed |
| US-4845265-A | RAPID CURING; SOLVENT RESISTANT COATINGS | ALLIED-SIGNAL INC. (US) | 1989-07-04 | — | — | US | disclosed |
| US-4775732-A | HIGH SPEED CURING | ALLIED-SIGNAL INC. (US) | 1988-10-04 | — | — | US | disclosed |
| US-4767883-A | PHOTORESISTS; FLEXIBILITY; LOW VISCOSITY, HIGH GLASS TRANSITION TEMPERATURE; CROSSLINKABLE | EASTMAN KODAK COMPANY (US) | 1988-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301114-A1 | POLYCARBONATE DIOL AND PRODUCING METHOD THEREOF, AND POLYURETHANE AND ACTIVE ENERGY RAY-CURABLE POLYMER COMPOSITION BOTH FORMED USING SAME | DIMT1, CAD, PUF60 | CYP4F2 3316/4885CYP4A11 2863/4885USP2 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.